- Home
- CMPO vs SNDX Comparison
CMPO vs SNDX Comparison
Compare CMPO & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPO
- SNDX
- Stock Information
- Founded
- CMPO 2000
- SNDX 2005
- Country
- CMPO United States
- SNDX United States
- Employees
- CMPO N/A
- SNDX N/A
- Industry
- CMPO Finance: Consumer Services
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- CMPO Finance
- SNDX Health Care
- Exchange
- CMPO Nasdaq
- SNDX Nasdaq
- Market Cap
- CMPO 1.2B
- SNDX 1.1B
- IPO Year
- CMPO N/A
- SNDX 2016
- Fundamental
- Price
- CMPO $14.28
- SNDX $9.63
- Analyst Decision
- CMPO Strong Buy
- SNDX Strong Buy
- Analyst Count
- CMPO 8
- SNDX 11
- Target Price
- CMPO $16.19
- SNDX $34.00
- AVG Volume (30 Days)
- CMPO 757.6K
- SNDX 1.8M
- Earning Date
- CMPO 08-07-2025
- SNDX 08-04-2025
- Dividend Yield
- CMPO N/A
- SNDX N/A
- EPS Growth
- CMPO N/A
- SNDX N/A
- EPS
- CMPO N/A
- SNDX N/A
- Revenue
- CMPO $376,385,000.00
- SNDX $43,722,000.00
- Revenue This Year
- CMPO $7.79
- SNDX $431.08
- Revenue Next Year
- CMPO $8.61
- SNDX $105.38
- P/E Ratio
- CMPO N/A
- SNDX N/A
- Revenue Growth
- CMPO N/A
- SNDX N/A
- 52 Week Low
- CMPO $6.08
- SNDX $8.58
- 52 Week High
- CMPO $15.20
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- CMPO 48.91
- SNDX 48.78
- Support Level
- CMPO $14.51
- SNDX $9.03
- Resistance Level
- CMPO $15.20
- SNDX $10.54
- Average True Range (ATR)
- CMPO 0.39
- SNDX 0.53
- MACD
- CMPO -0.07
- SNDX 0.12
- Stochastic Oscillator
- CMPO 13.21
- SNDX 50.27
About CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform. It has two reportable segments: Payment Card and Arculus.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.